{"id":649051,"date":"2023-04-26T11:32:02","date_gmt":"2023-04-26T11:32:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=649051"},"modified":"2023-04-26T11:32:02","modified_gmt":"2023-04-26T11:32:02","slug":"haier-biomedicals-2022-corporate-social-responsibility-report-released","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/haier-biomedicals-2022-corporate-social-responsibility-report-released_649051.html","title":{"rendered":"Haier Biomedical\u2019s 2022 Corporate Social Responsibility Report Released"},"content":{"rendered":"
On March 28, Haier Biomedical released its 2022 Corporate Social Responsibility Report (\u201cReport\u201d), which discloses the company\u2019s responsible practices in the areas of corporate governance, environment, and society.<\/div>\n

On March 28, Haier Biomedical<\/a> released its 2022 Corporate Social Responsibility Report (“Report”), which discloses the company’s responsible practices in the areas of corporate governance, environment, and society. In 2022, in line with its corporate social responsibility vision of “Smart Life, Shared Future”, Haier Biomedical has constructed a life-centric corporate social responsibility model that focuses on leadership, integrity, future, and ecosystem, and gave back to the society through concrete actions.<\/p>\n

 \"\"<\/p>\n

The report pointed out that Haier Biomedical’s operating income in 2022 was $41.43million, while the total global tax burden was $30.42million. The company also provided society with a total of 2690 job opportunities, greatly contributing to social development and people’s livelihood.<\/p>\n

Commitment to innovative technology and digital wisdom to safeguard life and health.<\/strong><\/p>\n

Advanced technology self-sufficiency is the only way to promote quality development. As a brand of the digital scene of life sciences and medical innovation based on the transformation of the Internet of Things, Haier Biomedical has always been committed to innovative technology and promoted the integration of inventive technology with the ecosystem. The company strives to establish a benchmark for the industry’s “smartness”, help develop the modern industrial system, support major strategic projects such as biological safety, food safety, genetic safety, biological diversity, and a Healthy China, build a national security barrier, and safeguard the public’s health and safety.<\/p>\n

The report reveals that in 2022, Haier Biomedical’s investment cost was $429million, an increase of 23.77% year-on-year, and its R&D personnel totaled 897 people, an increase of 59% year-on-year, showing an upward trend for four consecutive years. Utilizing global R&D resources, the company has established an open R&D model that connects site, laboratory, and market, and has innovative platforms that have been nationally approved, including post-doctoral research workstations, national enterprise technology centers, and Shandong Provincial Engineering Research Center. As of the end of 2022, Haier Biomedical has a total of 795 patents and 114 software copyrights, in addition to 131 new invention patent applications. The company has also led or participated in the development of 32 international, national, industry, and group standards and technical specifications, and has received 24 scientific and technological awards at or above the provincial level. Furthermore, the company has 28 technological achievements that have been deemed to meet international standards, contributing to its strength, global standing and demonstrating and guiding the industry.<\/p>\n

Consolidate the foundation of business governance, and establish an integrity-based win-win ecosystem.<\/strong><\/p>\n

If technological innovation strength is the foundation for encouraging enterprises to grow larger and more powerful, advanced business management philosophies are the key to enterprises. Haier Biomedical is committed to establishing an integrity-based win-win enterprise ecosystem, conducts corporate governance in accordance with the highest standards of business ethics and corporate governance requirements, and strictly prevents corporate risks to maximize the shareholders’ long-term value. The company also insists on a diverse board of directors and the provision of professional opinions from a range of perspectives to promote its sustainable and healthy development. During the reported period, the proportion of women on the board of directors was 36%, the company hosted over 160 receptions for investors, with a total of over 1900 investors. Haier Biomedical has also continued to improve its risk management system to ensure corporate stability, while adhering to commercial ethics and serving as a model for socially responsible enterprise.<\/p>\n

According to the report, Haier Biomedical has received several honors and recognition in 2022. While being included in the Northbound Trading Link, SSE 380 Index, FTSE GEIS Index, and China Stock Exchange Xinhua National Brand Engineering Index, the company was also selected by the index of Biomedicine in Shanghai Branch, ranking 5 major heavy stocks. In addition, the company has been included in a number of important lists, including the top 500 new economic enterprises in China, the top 50 science and technology enterprises, and the top 30 companies that supply medical equipment in China.<\/p>\n

Furthermore, Haier Biomedical remains faithful to its philosophy of “respect for life” in terms of its product quality, and established a comprehensive quality control system for R&D, procurement, manufacturing, and services. It also always prioritizes the user experience, and is committed to expanding its business’s ecological footprint. The report shows that in 2022, Haier Biomedical has a 0% recall rate and a 99.8% user satisfaction rate. The company also received a number of prestigious certifications, including ISO9001 and Rhein ISO13485, and was recognized as one of the national product and service quality integrity demonstration enterprises and national medical device industry quality leading brand.<\/p>\n

Unleash the potential of innovation and development and seek human health and well-being.<\/strong><\/p>\n

Employees are the cornerstone of the company’s development. By providing employees with a diverse, healthy, safe, and happy working environment, Haier Biomedical established an open and practical talent system that stimulates employees’ individual potential and provides them with a better future. At the same time, it promotes medical treatment through its own technological innovation advantages and influence, and shares development results with the community to help achieve medical treatment equity on a global scale.<\/p>\n

Haier Biomedical has established an open and practical talent acquisition system based on the management philosophy of “non-discrimination, diversity, and equal opportunities” and the Rendanheyi management model. In 2022, the company attracted a total of 778 talents, and provided each employee with a thriving innovation and entrepreneurial platform, allowing employees to maximize their potential and attain personal value. Utilizing the core advantages of their own life science and medical innovation, Haier Biomedical also joins hands with global ecological partners to contribute to social medical public welfare, accelerate the popularization of medical technology, promote the inclusivity and sharing of quality medical resources, and continuously implement corporate citizen responsibilities, thereby further promoting the construction of a global community of health for all and actively engaging Chinese influences in global medical and health undertakings.<\/p>\n

According to the report, in 2022, Haier Biomedical donated cash, materials, and equipment totaling $53 million, as well as other medical product services totaling $8.8 million,. The company also provided services to over 10,000 hospitals, over 5500 disease control units, over 3400 biopharmaceutical companies, and over 1700 college scientific research institutions. In addition, it actively promotes the joint construction of a global community of health for all to aid in the industrial upgrading of various countries and the improvement of people’s livelihood. At present, more than 130 countries and regions across the globe have adopted the company’s scenario solutions and services, contributing to the improvement of public health in underdeveloped countries and regions.<\/p>\n

Incorporate green science and technology genes and lead green transformation and development.<\/strong><\/p>\n

2022 is key to global sustainable development and China’s implementation of the dual carbon goal. As a science and technology enterprise, Haier Biomedical actively responded to the call of the 20th National Congress of the Communist Party of China and collaborated to contribute to the country’s development on the basis of a harmonious coexistence between people and nature. It reduced carbon emissions based on green buildings, green design, green procurement, green manufacturing, green logistics, green office, and other means, contributing scientific and technological power to create a beautiful China with green hills, clear water, and fresh air.<\/p>\n

On the path to green ecological development, Haier Biomedical, driven by green technology innovation, integrates green science and technology into its development. From making a breakthrough in the key technologies of HC hydrocarbon and reducing as high as 50% of energy costs in the first energy-saving core series ultra-low temperature refrigerator, to overcoming the technical challenges of large-cooling Stirling, the company initiated the industry’s green low-carbon development phase, and developed “Shenlan”, the world’s first -150°C IoT deep low-temperature hydrocarbon refrigerator, leading the industry’s green transformation and development via carbon reduction practices enabled by technological innovation.<\/p>\n

The report indicates that in 2022, Haier Biomedical’s annual power generation from photovoltaic power generation equipment reached 1.489 million kWh, which reduced carbon emissions by 865.69 tons. In particular, its vaccine refrigerators from the solar direct drive solution reduced carbon emissions by 109,500 tons per year, which is equivalent to the amount of carbon neutralized by 4500 acres of mature forests. In addition, Haier Biomedical has received the industry’s first energy-saving and environmental protection certification for medical refrigerators, with a total of 69 energy-saving and environmental protection certificates for 51 models. Focusing on its own green practices, and its factories’ green and smart development, Haier Biomedical is committed to creating green factories that serve as an industry demonstrative model. In 2022, Haier Biomedical was designated a national green factory and a municipal green factory in Qingdao.<\/p>\n

In the first year of comprehensive implementation of the spirit of the 20th National Congress of the Communist Party of China, Haier Biomedical keeps in mind the country’s top priorities and forges ahead with confidence and fortitude by taking the initiative to assume corporate responsibility, actively implementing national strategic needs, continuously improving multi-level and multi-chain service capabilities, and more effectively empowering industrial progress to make life better through the intelligent protection of life science.<\/p>\n

original source: https:\/\/www.haiermedical.com\/news\/Haier-Biomedical-2022-Corporate-Social-Responsibility-Report-Released.html<\/a><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Haier Biomedical<\/a>
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +86-532-88935593
Country:<\/strong> China
Website:<\/strong> https:\/\/www.haiermedical.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

On March 28, Haier Biomedical released its 2022 Corporate Social Responsibility Report (\u201cReport\u201d), which discloses the company\u2019s responsible practices in the areas of corporate governance, environment, and society. On March 28, Haier Biomedical released its 2022 Corporate Social Responsibility Report (“Report”), which … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[410,417,406,404,416],"tags":[],"class_list":["post-649051","post","type-post","status-publish","format-standard","hentry","category-Manufacturing-Industry","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-US","category-World"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/649051","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=649051"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/649051\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=649051"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=649051"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=649051"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}